PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Clinical application of oral meglumine diatrizoate esophagogram in screening esophageal fistula during radiotherapy for esophageal cancer.

Abstract Esophageal fistula is a serious and common complication of radiotherapy for esophageal cancer. Therefore, early diagnosis and treatment is necessary. Because of side effect of barium esophagography, it cannot be used to screening esophageal fistula during radiotherapy. Meglumine diatrizoate is an ionic contrast agent, its adverse reactions were rarely seen when it was used in the body cavity. The purpose of this trial is identified the sensitivity and specificity of oral meglumine diatrizoate in an esophagogram for screening esophageal fistula during radiotherapy.
PMID
Related Publications

Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy.

Morphologic endothelial response to meglumine diatrizoate: an electron-microscopic study.

Computed body tomography with a new nonionic contrast agent. Comparison of ioversol with sodium/meglumine diatrizoate.

The effects of high (sodium meglumine diatrizoate, Renografin-76) and low osmolar (sodium meglumine ioxaglate, Hexabrix) radiographic contrast media on diastolic function during left ventriculography in patients.

Prospective randomized trial of iohexol 350 versus meglumine sodium diatrizoate as an oral contrast agent for abdominopelvic computed tomography.

Authors

Mayor MeshTerms

Esophageal Neoplasms

Keywords
Journal Title medicine
Publication Year Start




PMID- 29718892
OWN - NLM
STAT- MEDLINE
DCOM- 20180509
LR  - 20180509
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 18
DP  - 2018 May
TI  - Clinical application of oral meglumine diatrizoate esophagogram in screening
      esophageal fistula during radiotherapy for esophageal cancer.
PG  - e0668
LID - 10.1097/MD.0000000000010668 [doi]
AB  - INTRODUCTION: Esophageal fistula is a serious and common complication of
      radiotherapy for esophageal cancer. Therefore, early diagnosis and treatment is
      necessary. Because of side effect of barium esophagography, it cannot be used to 
      screening esophageal fistula during radiotherapy. Meglumine diatrizoate is an
      ionic contrast agent, its adverse reactions were rarely seen when it was used in 
      the body cavity. The purpose of this trial is identified the sensitivity and
      specificity of oral meglumine diatrizoate in an esophagogram for screening
      esophageal fistula during radiotherapy. METHODS/DESIGN: This trial was a
      prospective, multicenter, diagnostic clinical trial. A total of 105 patients with
      esophageal cancer will swallowed meglumine diatrizoate and underwent a
      radiographic examination weekly during radiotherapy, medical personnel observed
      the esophageal lesions to determine whether an esophageal fistula formed. If an
      esophageal fistula was observed, esophagofiberoscopy and/or computer tomography
      was used to further confirm the diagnosis. And the sensitivity and specificity of
      meglumine diatrizoate should be calculated for screening esophageal fistula
      during radiotherapy. DISCUSSION: To our knowledge, this study protocol is the
      first to identify the sensitivity and specificity of oral meglumine diatrizoate
      in an esophagogram for screening esophageal fistula during radiotherapy. If oral 
      meglumine diatrizoate can be used to screening esophageal fistula, more patients 
      will benefit from early detection and treatment.
FAU - Geng, Lidan
AU  - Geng L
AD  - Department of Oncology, Mianyang Central Hospital, Mianyang.
AD  - Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nan
      Chong.
FAU - Wu, Rong
AU  - Wu R
AD  - Department of Oncology, Mianyang Central Hospital, Mianyang.
FAU - Hu, He
AU  - Hu H
AD  - Department of Oncology, Yan Ting County Cancer Hospital, Yan Ting.
FAU - Zhao, Yu
AU  - Zhao Y
AD  - Department of Oncology.
FAU - Fan, Lingli
AU  - Fan L
AD  - Department of Oncology, Mianyang Central Hospital, Mianyang.
FAU - Zhao, Zhenhua
AU  - Zhao Z
AD  - Department of Oncology, Mianyang Central Hospital, Mianyang.
FAU - Liao, Dongbiao
AU  - Liao D
AD  - Department of Oncology, Mianyang Central Hospital, Mianyang.
FAU - Li, Musheng
AU  - Li M
AD  - Department of Radiology.
FAU - Xiang, Miao
AU  - Xiang M
AD  - Department of Oncology, Mianyang Central Hospital, Mianyang.
FAU - Ma, Ying
AU  - Ma Y
AD  - Department of Scientific Research and Education, Mianyang Central Hospital,
      Mianyang, People's Republic of China.
FAU - Du, Xiaobo
AU  - Du X
AD  - Department of Oncology, Mianyang Central Hospital, Mianyang.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Contrast Media)
RN  - 3X9MR4N98U (Diatrizoate Meglumine)
SB  - AIM
SB  - IM
MH  - Adult
MH  - China
MH  - Contrast Media/pharmacology
MH  - Diatrizoate Meglumine/*pharmacology
MH  - Early Diagnosis
MH  - Esophageal Fistula/diagnosis/etiology
MH  - *Esophageal Neoplasms/pathology/radiotherapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Mass Screening/methods
MH  - Radiography/*methods
MH  - Radiotherapy/*adverse effects/methods
MH  - Sensitivity and Specificity
EDAT- 2018/05/03 06:00
MHDA- 2018/05/10 06:00
CRDT- 2018/05/03 06:00
PHST- 2018/05/03 06:00 [entrez]
PHST- 2018/05/03 06:00 [pubmed]
PHST- 2018/05/10 06:00 [medline]
AID - 10.1097/MD.0000000000010668 [doi]
AID - 00005792-201805040-00060 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 May;97(18):e0668. doi: 10.1097/MD.0000000000010668.